USE OF CELIPROLOL FOR TREATING VASCULAR EHLERS-DANLOS SYNDROME IN WOMEN DURING PREGNANCY AND PERIPARTUM PERIOD
The present disclosure relates to the use of celiprolol or a pharmaceutically acceptable salt thereof for treating vascular Ehlers-Danlos syndrome in women during pregnancy and peripartum period.
1 . A method for treating vascular Ehlers-Danlos syndrome in a woman during pregnancy, during delivery, or during the peripartum period, the method comprising administering celiprolol, or a pharmaceutically acceptable salt thereof, to the woman during pregnancy, during delivery, or during the peripartum period, thereby treating vascular Ehlers-Danlos syndrome in the woman.
2 . The method of claim 1 , wherein celiprolol, or a pharmaceutically acceptable salt thereof, is administered to the woman a dosage of at least 100 mg per day.
3 . The method of claim 1 , wherein celiprolol, or a pharmaceutically acceptable salt thereof, is administered to the woman at a dosage ranging from about 200 mg to about 600 mg per day.
4 . The method of claim 1 , wherein celiprolol, or a pharmaceutically acceptable salt thereof, is administered to the woman at a daily dosage of about 200 mg to about 400 mg.
5 . The method of claim 1 , wherein celiprolol, or the pharmaceutically acceptable salt thereof, is administered twice daily.
6 . The method of claim 1 , wherein the method prevents or reduces the risk of cardiovascular and/or digestive and/or obstetrical events.
7 . The method of claim 1 , wherein the method prevents or reduces the risk of arterial dissection and rupture.
8 . The method of claim 1 , wherein the method prevents or reduces the risk of obstetrical accidents.
9 . The method of claim 1 , wherein the method prevents or reduces the risk of uterine rupture.
10 . The method of claim 1 , wherein the method reduces the risk of pregnancy-related death.
11 . The method of claim 1 , wherein the method reduces the risk of death of the woman during the first year following termination of pregnancy.
12 . The method of claim 1 , wherein the method reduces the risk of preterm birth.
13 . The method of claim 1 , wherein the method does not result n neonatal hypoglycaemia or intrauterine growth retardation.
14 . The method of claim 1 , wherein the woman with vEDS has been treated with celiprolol or a pharmaceutically acceptable salt, and the dosage is not adjusted or reduced in anticipation of becoming pregnant or after confirmation of pregnancy.
15 . The method of claim 1 , wherein the dosage is not adjusted or reduced during pregnancy, during delivery and/or during the peripartum period.
16 . A method for treating vascular Ehlers-Danlos syndrome in a woman in need thereof, the method comprising continuing administration of celiprolol or a pharmaceutically acceptable salt without dose adjustment to a woman who has been treated with celiprolol or a pharmaceutically acceptable salt, and who may become pregnant or is confirmed of being pregnant.
17 . The method of claim 16 , wherein the dosage is at least 100 mg per day.
18 . The method of claim 16 , wherein the dosage ranges from about 200 mg to about 600 mg per day.
19 . The method of claim 16 , wherein the dosage is at least 100 mg celiprolol hydrochloride per day.
20 . The method of claim 16 , wherein the dosage ranges from about 200 mg to about 600 mg celiprolol hydrochloride per day.